UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Epilepsia (Copenhagen), 2020-09, Vol.61 (9), p.1854-1868

2020

Volltextzugriff (PDF)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

CNS drugs, 2018-11, Vol.32 (11), p.1053-1067

2018

Volltextzugriff (PDF)

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

Journal of clinical pharmacology, 2019-08, Vol.59 (8), p.1110-1119

2019

Volltextzugriff (PDF)

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

Epilepsia (Copenhagen), 2020-02, Vol.61 (2), p.267-277

2020

Volltextzugriff (PDF)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

Clinical pharmacology in drug development, 2019-11, Vol.8 (8), p.1009-1031

2019

Volltextzugriff (PDF)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

Clinical pharmacokinetics, 2020-06, Vol.59 (6), p.747-755

2020

Volltextzugriff (PDF)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

Neurology, 2018-04, Vol.90 (14), p.e1204

2018

Volltextzugriff (PDF)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam

Journal of clinical pharmacology, 2020-10, Vol.60 (10), p.1304-1313

2020

Volltextzugriff (PDF)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

Acta neurologica Scandinavica, 2020-12, Vol.142 (6), p.531-540

2020

Volltextzugriff (PDF)

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors

American journal of clinical oncology, 2009-02, Vol.32 (1), p.9-14

2009

Volltextzugriff (PDF)

Correction to: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

CNS drugs, 2019-04, Vol.33 (4), p.397-397

2019

Volltextzugriff (PDF)

A Phase I, Randomized, Double.Blind, Placebo.Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

CNS drugs, 2018-11, Vol.32 (11), p.1053-1067

2018

Volltextzugriff (PDF)

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

CNS drugs, 2020-06, Vol.34 (6), p.661-672

2020

Volltextzugriff (PDF)

Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy

Epilepsy & behavior, 2019-12, Vol.101, p.106735, Article 106735

2019

Volltextzugriff (PDF)

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Leukemia & lymphoma, 2015-02, Vol.56 (2), p.395-400

2015

Volltextzugriff (PDF)

Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT329-CT329

2015

Volltextzugriff (PDF)

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes

Leukemia & lymphoma, 2015-02, Vol.56 (2), p.395-400

2015

Volltextzugriff (PDF)

Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin

Journal of pharmaceutical and biomedical analysis, 2000-12, Vol.24 (1), p.1-10

2000

Volltextzugriff (PDF)

Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy

Cancer chemotherapy and pharmacology, 1990-01, Vol.25 (4), p.286-290

1990

Volltextzugriff (PDF)

Pharmacokinetic Aspects of Multiple Dose Studies

Drug Discovery and Evaluation: Methods in Clinical Pharmacology, p.683-693

Volltextzugriff (PDF)

Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo

European journal of cancer (1990), 1992, Vol.28 (1), p.28-31

1992

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer

Cancer chemotherapy and pharmacology, 1990-01, Vol.26 (4), p.283-287

1990

Volltextzugriff (PDF)

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Leukemia & Lymphoma, 2015, Vol.56 (2), p.395-400

2015

Volltextzugriff (PDF)

Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4′-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues

Biochemical pharmacology, 1987-05, Vol.36 (9), p.1521-1526

1987

Volltextzugriff (PDF)

Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector

Journal of chromatography. Biomedical applications, 1986, Vol.381, p.373-384

1986

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(59)

Publikationsform

Sprache

Englisch
(69)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors

Correction to: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

A Phase I, Randomized, Double.Blind, Placebo.Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes

Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin

Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy

Pharmacokinetic Aspects of Multiple Dose Studies

Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo

Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4′-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues

Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector

Suchergebnisse filtern